Email: [email protected]
5th Floor, Building B, No.57,Keji 3rd Road,High-Tech Zone, Xi'an,710075,China
No 6, Caotang Industry Park, No.2 Qinling Road, Hi-tech Zone, Xi'an, China
Paclitaxel was first isolated in 1971 from the Pacific yew and approved for medical use in 1993. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Paclitaxel powder is a chemotherapy drug that is given as a treatment for some types of cancer. Paclitaxel powder is a mitotic inhibitor now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.
Paclitaxel powder works by interfering with normal microtubule breakdown during cell division. Together with docetaxel, it forms the drug category of the taxanes. paclitaxel powder was the subject of a notable total synthesis by Robert A. Holton.
As well as offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. There was originally concern because of the environmental impact of its original sourcing, no longer used, from the Pacific yew. The assignment of rights, and even the name itself, to BMS were the subject of public debate and Congressional hearings.
It is a kind of anticancer drugs. It has the curative effect on many kinds of cancers, extremely on the ovarian cancer, breast cancer. Its cure rate reaches to 33%, effectiveness to 75%.
Paclitaxel is approved in the UK for ovarian, breast and lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma. It is recommended in NICE guidance of June 2001 that it should be used for nonsmall cell lung cancer in patients unsuitable for curative treatment, and in first-line and second-line treatment of ovarian cancer. In September 2001, NICE recommended paclitaxel should be available for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. In 2005, its use in the United States for the treatment of breast, pancreatic, and non-small cell lung cancers was approved by the FDA.
Common side effects include hair loss(Our product Minoxidil powder can treat it), bone marrow suppression, numbness, allergic reactions, muscle pains, and diarrhea. Other serious side effects include heart problems, increased risk of infection, and lung inflammation. Use during pregnancy may result in harm to the fetus.Paclitaxel is in the taxane family of medications. It works by interference with the normal function of microtubules during cell division.
If you need this product, please contact us at any time [email protected].
Previous: Quality Control of Icariin 90% HPLC